SGLT2 inhibitors contribute to weight loss, which is strongly associated with a decrease in hepatic lipid loss [61], and MASLD patients combined with T2DM have a tendency to ketoacidosis when administrated with Empagliflozin [70]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.